Q32 Bio Inc. and Homology Medicines, Inc. have agreed to a definitive merger agreement in an all-stock transaction. The consolidated company will keep the Q32 Bio Inc. name and be headquartered in Waltham, Massachusetts. Q32 has also regained all rights from Amgen for bempikibart, a drug in Phase 2 trials for treating autoimmune diseases atopic dermatitis and alopecia areata. Concurrently, Q32 Bio agreed to a $42 million private investment to support clinical development.
The Chaya_006 Alert: OT Edge Devices Under Fire
The Chaya_006 Edge Campaign Forescout’s Vedere Labs just dropped a threat briefing on a campaign they’re tracking as Chaya_006, and it’s a textbook example of
